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Abstract 
Objectives: There is a lack of research examining the incidence of health anxiety in Chronic 
Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), even though this is an important 
research area with potentially significant clinical implications. This preliminary study aims to 
determine the incidence of anxiety and depression, more specifically health anxiety, in a sample 
of CFS/ME patients over a three month period. 
Design: The research was a cross-sectional questionnaire-based study, using a consecutive 
sample of patients who were assessed in a CFS/ME service. 
Method: Data was taken from the Short Health Anxiety Inventory and the Hospital Anxiety and 
Depression Scale to identify incidence of anxiety, depression and health anxiety.  
Results: Data was collected from 45 CFS/ME patients over the sampling period. Thirty-one 
patients (68.9%) scored above the normal range but within the sub-clinical range of health anxiety 
and 19 patients (42.2%) scored within the clinically significant health anxiety range. Anxiety and 
depression were common, with prevalence rates of 42.2% and 33.3% respectively, which is 
comparable to data found in a recent large scale trial.  
Conclusions: Health anxiety in CFS/ME patients is likely to be common and warrants further 
investigation to provide a better insight into how this may influence treatment and symptom 
management.  
 
Key words: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME); health anxiety; 
anxiety; depression.  
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Practitioner Points 
• Anxiety and depression were common in a sample of CFS/ME patients, with a high 
proportion meeting criteria for severe health anxiety. 
• While CFS/ME and health anxiety are distinct and separate conditions, it is unsurprising 
that patients with CFS/ME, who commonly report feeling ‘delegitimised’, may experience 
high levels of anxiety relating to their physical symptoms 
• Clinicians should consider screening for health anxiety due to the possible clinical 
implications for treatment; mutual maintenance may negatively influence treatment 
success in a complex condition such as CFS/ME 
• Health anxiety has been found to be common across other chronic medical conditions 
but has been shown to be effectively treated with appropriately tailored interventions. 
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Introduction  
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a debilitating condition 
characterised by excessive fatigue, joint pain and sleep disturbance.  With prevalence rates of 
CFS/ME estimated at 0.17- 2.07% (Johnston et al., 2013), developing an efficacious and cost-
effective treatment is a priority. However, the aetiology of CFS/ME remains poorly understood 
and treatment falls short of optimal outcomes: a recent meta-analysis (Castell, Kazantzis & 
Moss-Morris, 2011) indicated that gold standard treatment Cognitive Behaviour Therapy (CBT) 
(NICE, 2007) demonstrates only moderate improvements (g=0.33).  A recent study reported that 
32% of the CFS/ME sample experienced co-morbid anxiety disorders (White et al., 2011). Due 
to the complex and heterogenous nature of this condition, it would be unsurprising if patients 
with CFS/ME experience high levels of health focussed anxiety.   
High levels of health anxiety have been found to be common across a diverse range of medical 
conditions including cardiac, neurological and respiratory conditions (Tyrer et al., 2011), however 
no data exists on the incidence of health focussed anxiety in CFS/ME.  
Individuals with CFS/ME commonly report symptom hypervigilance and beliefs that CFS/ME is 
serious and physiological in origin (Moss-Morris, 2005; Moss-Morris & Petrie, 2000), factors also 
found to maintain health anxiety (Salkovskis, 1996).  
 
The aim of this preliminary study is to determine incidence of anxiety, depression, and specifically 
health anxiety in CFS/ME. Data will expand our understanding of this population and develop 
treatments to address outstanding clinical needs. 
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Method 
Participants and recruitment 
Recruitment spanned a 3-month period. Adults with a diagnosis of CFS/ME were recruited from 
a CFS/ME service offering evidence based multidisciplinary assessment and treatment as per 
NICE guidance (2007) (including psychology, physiotherapy and occupational therapy). Clinicians 
diagnosed patients according to the Fukuda criteria (Fukuda et al., 1994) during an assessment 
interview.  A battery of standardised questionnaires assisted in diagnosis (table 1).  
Measures 
This study used two of the questionnaires included in the battery: the Hospital Anxiety and 
Depression Scale (HADS; Zigmond & Snaith, 1990), and the Short Health Anxiety Inventory 
(SHAI; Salkovskis et al., 2002). Both measures consisted of 14 items using a 4 point likert scale 
(scoring 0-3) where higher scores indicate higher levels of health anxiety, and anxiety/depression. 
The HADS is separated into two 7-item subscales of anxiety and depression” 
Both measures demonstrated reliability across numerous patient groups (Brennan et al., 2010; 
Alberts et al., 2013, respectively). A cut-off of 11 on the HADS was used to identify ‘definite’ cases 
of depression/anxiety (Brennan et al., 2010). A cut-off of 15 on the SHAI indicates above the 
normal range, but sub-clinical health anxiety (3 s.d. above the norm), 18 indicates significant 
levels of health anxiety (Rode et al., 2006).  
We retained data relating to scores between 15-18 (sub-clinical health anxiety) as this is the first 
paper to explore incidence of health anxiety in CFS/ME and we believe it is of clinical interest to 
describe and report the group showing rates of health anxiety that are elevated from the norm. 
  
[Insert Table 1] 
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Statistical analyses 
Data were normally distributed therefore a Pearson’s product moment correlation was used to 
assess association and convergent validity. An independent t-test was used to test differences 
between dichotomous variables.  
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Results 
Eighty-seven patients attended the service during the sampling period. Of these, 77 were 
diagnosed with CFS/ME (89%), 49 consented to the study and 45 provided full data (58% of 
overall sample). 
 
[Insert Table 2] 
 
In this study the HADS anxiety and depression subscales and SHAI demonstrated good internal 
consistency (Cronbach's α = .80, .84, .89, respectively).  
 
HADS data indicated that 42.2% of participants scored over the cut–off for ‘definite’ anxiety, 
33.3% scored above the cut-off for ‘definite’ depression. On the SHAI, 68.9% scored within the 
range of sub-clinical health anxiety, 42.2% scored in the significant health anxiety range.  See 
table 2 for further descriptive statistics.   
Correlational analysis between the SHAI and HADS-A indicated a moderate strength association, 
confirming expected levels of convergent validity (r (45) = .353, p = .017). 
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Frequencies of definite cases on SHAI and HADS was used to devise a contingency table, 
indicating that sensitivity of the HADS-A (‘definite case’) to predict clinically significant health 
anxiety on the SHAI is 58%, specificity calculations indicate 69% of patients who did not reach 
definite case on the HADS would also not reach clinically significant health anxiety on the SHAI 
(table 3).  
 This is consistent with correlational analysis and clinical expectations: a proportion of patients 
with ‘severe general anxiety’ also have specific anxiety associated with their health others; have 
case levels of general anxiety without health related features.  
 
[Insert Table 3] 
 
There were no significant differences between the SHAI scores for males (M = 17.43 SD = 7.12) 
and females (M = 18.06 SD = 7.63); t(43) = -.26, p = .73), nor age ( r = -.25, n = 45, p = .10).   
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Discussion 
The aim of this preliminary study was to establish incidence of anxiety, depression, and specifically health 
anxiety in CFS/ME. We believed that this information would contribute to an understanding of how targeted 
treatments can be developed to address the clinical needs of this population. 
Findings are consistent with existing literature reporting high incidence of anxiety and depression 
in patients with CFS/ME (White et al., 2011). This study found a high incidence of health anxiety 
(42.2%) in comparison to the 24.7% reported in other medical settings (Tyrer et al., 2011). With 
uncertain prognosis, heterogeneous manifestation, as well as health professionals viewing the 
condition as contentious and lacking confidence and knowledge (Bayliss et al., 2016), it is 
understandable that CFS/ME may cause patients to worry about their health. 
Participants completed questionnaires prior to their initial appointment, therefore the high 
incidence in this study may reflect elevated anxiety associated with the assessment process this 
should be explored further.  
The mean SHAI score for the present sample (17.9) was higher than norms established for other 
health groups such as gastroenterology patients (11.4), General Practice patients (11.2) and 
anxiety sufferers (14.9) (Salkovskis et al., 2002). This finding contributes to the knowledge base 
relating to health anxiety across health conditions, but is of particular clinical interest given the 
complex nature of CFS/ME and the suggested interplay between health anxiety and CFS/ME in 
clinical practice (Daniels & Loades, 2016).  
The small sample, modest response rate and disproportion number of females and Caucasian 
participants limited the generalizability of the results. A larger-scale study with a more 
representative sample could be used to replicate findings and establish more definitive normative 
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data for the SHAI in CFS/ME Future studies should give consideration to other key variables such 
as illness duration which were not explored within this preliminary paper.   
 
Anecdotal feedback from the service lead indicated that a number of patients declined to 
participate due to the perceived implication that anxiety was the primary complaint rather than 
chronic fatigue: “one patient said crossly ‘I'm not a hypochondriac” (personal communication, 
Gladwell, 2014). This is consistent with high illness convictions commonly found amongst patients 
with CFS/ME (Moss-Morris, 2005; Moss-Morris & Petrie, 2000); patients may have interpreted the 
questionnaire as a rejection of an underlying physiological explanation for CFS/ME. Further 
research should explore the acceptability of this measure in the CFS/ME population and its 
suitability in capturing relevant data. 
 
Results indicate that there may be high incidence of health anxiety in CFS/ME, which has been 
previously unreported. It is likely that severe health anxiety would impede treatment of CFS/ME 
if neglected as a clinical issue due to the complex and mutually maintaining nature of these 
conditions which share similar theoretical underpinnings and clinical features (Daniels & Loades, 
2016). A recent large scale treatment trial CHAMP (Cognitive behaviour therapy for Health 
Anxiety in Medical Patients, Tyrer et al., 2014) yielded positive and cost-neutral outcomes in 
patients who experienced comorbid health anxiety and medical problems. Based on current 
findings, future research should build on Daniels & Loades (2016) work to establish whether 
adapted CBT for health anxiety in medical problems could optimise outcomes for the CFS/ME 
subgroup who experience significant levels of health focussed anxiety. 
 
 
.  
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Table 1.  
Fukuda Diagnostic Criteria and Questionnaire Measures 
Major 
Criterion 
Symptoms Signs Questionnaire 
measures 
Major 
criterion: New 
onset of 
fatigue 
causing 50% 
reduction in 
activity for at 
least 6 
months 
 
Minor 
criterion:  
Presence of 8 
of the 11 
symptoms 
and 2 of the 3 
signs  
 
• Mild Fever 
• Recurrent sore throat 
• Painful lymph nodes 
• Muscle weakness 
• Muscle pain 
• Prolonged fatigue after 
exercise 
• Recurrent headache 
• Migratory joint pain 
• Neurological or 
psychological complains, 
including sensitivity to bright 
lights forgetfulness, 
confusion, inability to 
concentrate, excessive 
irritability, and depression 
• Sleep disturbance 
(hypersomnia or insomnia) 
• Sudden onset of symptom 
complex 
• Low-grade 
fever 
• Non 
exudative 
pharyngitis 
• Palpable or 
tender 
lymph 
nodes 
• Chalder 
Fatigue 
Scale 
• SF-36 
• EQ-5D 
• Hospital 
Anxiety 
and 
Depression 
Scale 
• Health 
Anxiety 
Inventory 
• Self-
efficacy 
scale 
• Visual 
Analogue 
Scale 
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Table 2.  
Demographic information and clinical findings 
   
CFS/ME participants (n= 45) 
 
Gender 
 
14 Male: 31 Female 
Mean age (SD) 38.7 years (13.1) 
Ethnicity 43 White: 2 Asian 
Mean HADS-A score (SD) 10.0 (4.7) 
Mean HADS-D score (SD) 8.9 (3.8) 
Number (%) of participants with HADS-A score ≥ 
11 
19 (42.2) 
Number (%) of participants with HADS-D score ≥ 
11 
15 (33.3) 
Mean SHAI score (SD) 17.9 (7.4) 
Number (%) of participants with SHAI score ≥ 15 31  (68.9) 
Number (%) of participants with SHAI score ≥ 18  19 (42.2) 
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Table 3.  
Contingency table of HADS-A and SHAI “definite” cases 
 HADS- A  
 
Total 
Not Case 
(<11) 
Definite Case 
(≥ 11) 
 
SHAI 
 
Not clinically significant 
(<18) 
 
18 
 
8 
 
26 
Clinically significant  (≥ 18) 8 11 19 
Total 26 19 45 
